Big Pharma-backed antifibrotic startup Blade has triggered the remaining tranche of last summer’s $45 million series B after placing its bets on a leading…
Startup Vir Biotechnology, guided by former Biogen CEO George Scangos, is unveiling a multifaceted pipeline of treatments for infectious diseases.
In life sciences companies, collaboration is key. It’s important for operational leaders to partner with finance leaders to consider risks and issues that may…
Johnson & Johnson had painted sirukumab and talacotuzumab as future blockbusters that would drive growth for years. Today, J&J abandoned those plans.
Drug accelerator Cydan has gained a $34 million injection as it eyes deeper inroads into rare diseases for its second fund.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
Sanofi veteran Christopher Winter has been appointed as the new chief of R&D at drug discovery biotech Silicon.
The MET-TKI triggered partial responses in a significant minority of NSCLC patients who had progressed after treatment with an EGFR-TKI.
AstraZeneca admitted that some early data for Acerta's BTK inhibitor acalabrutinib was crooked.
The ALK inhibitor triggered responses in a significant minority of heavily pretreated patients, suggesting it can play a role in NSCLC treatment.
The antisense drug triggered a 20-point improvement against a score of neuropathy impairment, laying a marker for the upcoming showdown with Alnylam.
Roche will pay up to $387 million to license certain classes from the more than 100 groups of possibly novel antibiotics Warp Drive is analyzing.